Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5919_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
15 Мб
Скачать
☆
Polymer-Based Drug Delivery Systems: Design and Characterization 129
40. Borges FTP, Papavasiliou G, Teymour F (2020) Characterizing the molecular architec­ture of hydrogels and crosslinked polymer networks beyond Flory–Rehner—I. Theory. Biomacromolecules 21:5104–5118
41. Scott RA, Nicholas AP (1999) Highly cross­linked, PEG-containing tained solute delivery. Biomaterials 20:1371– 1380
42. Tani Y, Yonenuma R, Mori H (2023) Clusterization-triggered emission of poly (vinyl amine)-based ampholytic block and random copolymers. React Funct Polym 184:105518
43. Mahfufah U, Sultan NAF, Fitri AMN, Elim D, Mahfud MAS, Wafiah N, Friandini RA, Chabib L, Aliyah; Permana, A.D. (2023) Application of multipolymers system in the development of hydrogel-forming micronee­dle integrated with polyethylene glycol reser­voir for transdermal delivery of albendazole. Eur Polym J 183:111762
44. Xu B, Wang H, Luo Z, Yang J, Wang Z (2023) Multi-material 3D printing of mechanochromic double network hydrogels for on-demand patterning. ACS Appl Mater Interfaces 15:11122–11130
45. Lin Q, Hu Y, Qiu C, Li X, Sang S, McCle­ments DJ, Chen L, Long J, Xu X, Wang J et al (2023) Peanut protein-polysaccharide hydro­gels based on semi-interpenetrating networks used for 3D/4D printing. Food Hydrocoll 137:108332
46. Cerritelli S, Velluto D, Hubbell JA (2007) PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules 8:1966– 1972
47. Kolahdoozan M, Rahimi T, Taghizadeh A, Aghaei H (2023) Preparation of new hydro­gels by visible light cross-linking of dextran methacrylate and poly(ethylene glycol)­maleic acid copolymer. Int J Biol Macromol 227:1221–1233
48. Flemming M, Peppas NA (1999) Complexa­tion graft copolymer networks: swelling prop­erties, calcium binding and proteolytic enzyme inhibition. Biomaterials 20:1701– 1708
49. Xie S, Ren T, Chen G, Zhou Z, Li Z, Wu W, Huang L (2023) High-performance porous copolymer hydrogel for oceanic electricity generation. Chem Eng J 456:140983
50. Baranello MP, Bauer L, Benoit DSW (2014) Poly(styrene-alt-maleic anhydride)-based Diblock copolymer micelles exhibit versatile hydrophobic drug loading, drug-dependent
copolymers for sus-
release, and resistant ovarian cancer cells. Biomacromole­cules 15:2629–2641
51. Jose J, Athira VP, Michel H, Hafeela AR, Bhat SG, Thomas S, Maria LP (2023) Chapter 1— Hydrogels: an overview of the history, classi­fication, principles, applications, and kinetics. In: Thomas S, Sharma B, Jain P, She­khar S (eds) Sustainable Hydrogels. Elsevier, Amsterdam, pp 1–22
52. Rahman MS, Islam MM, Islam MS, Zaman A, Ahmed T, Biswas S, Sharmeen S, Rashid TU, Rahman MM (2019) Morphological charac­terization of hydrogels. In: Mondal M (ed) Cellulose-based superabsorbent hydro­gels. Springer, Cham, pp 819–863
53. Fergg F, Keil FJ, Quader H (2001) Investiga­tions of the microscopic structure of poly (vinyl alcohol) hydrogels by confocal laser scanning microscopy. Colloid Polym Sci 279: 61–67
54. Abuelfilat AY, Kim Y, Miller P, Hoo SP, Li J, Chan P, Fu J (2015) Bridging structure and mechanics of three-dimensional porous hydrogel with X-ray ultramicroscopy and atomic force microscopy. RSC Adv 5:63909– 63916
55. Cocarta AI, Hobzova R, Sirc J, Cerna T, Hrabeta J, Svojgr K, Pochop P, Kodetova M, Jedelska J, Bakowsky U et al (2019) Hydrogel implants for transscleral drug delivery for ret­inoblastoma treatment. Mater Sci Eng C 103: 109799
56. Longchamp A, Kaur K, Macabrey D, Dubuis C, Corpataux JM, De´glise S, Matson JB, Allagnat F (2019) Hydrogen sulfide­releasing peptide hydrogel limits the develop­ment of intimal hyperplasia in human vein segments. Acta Biomater 97:374
57. European Medicines Agency (2013) 2 Com­mittee for medicinal products for human use (CHMP) 3 joint MHLW/EMA reflection paper on the development of 4 block copoly­mer micelle medicinal products. European Medicines Agency, Amsterdam
58. Gao M, Yang Y, Bergfel A, Huang L, Zheng L, Bowden TM (2020) Self-assembly of cholesterol end-capped polymer micelles for controlled drug delivery. J Nanobiotech­nol 18:13.
s12951-020-0575-y
59. Scholz N, Determination of the critical micelle concen­tration of neutral and ionic surfactants with Fluorometry, Conductometry, and surface tension—A method comparison. J Fluoresc 28:465–476
internalization
https://doi.org/10.1186/
Behnke T, Resch-Genger U (2018)
by multidrug
130 Afroz Jahan et al.
60. McKenzie BE, Holder SJ, Sommerdijk NAJM (2012) Assessing internal structure of poly­mer assemblies from 2D to 3D CryoTEM: bicontinuous micelles. Curr Opin Colloid Interface Sci 17:343–349.
10.1016/j.cocis.2012.09.002
61. Gu PF, Xu H, Sui BW, Gou JX, Meng LK,
62. Puig-Rigall J, Ferna´ndez-Rubio C, Gonza´lez-
63. Negi P, Sharma G, Verma C, Garg P,
64. Jain S, Umamaheshwari RB, Bhadra D, Jain
65. Fang JY, Hwang TL, Leu YL (2003) Effect of
66. Lopez-Pinto JM, Gonza
67. Liu J, Hu G (2007) Advances in studies of
68. Godin B, Touitou E, Rubinstein E,
69. Maghraby GMME, Campbell M, Finnin BC
F, Wang XJ, Qi N, Zhang Y, He HB et al
Sun (2012) Polymeric micelles based on poly(eth­ylene glycol) block poly(racemic amino acids) hybrid polypeptides: conformation-facilitated drug-loading behavior and potential applica­tion as effective anticancer drug carriers. Int J Nanomedicine 7:109
Benito J, Houston JE, Radulescu A, Nguewa P, Gonza Structural characterization by scattering and spectroscopic methods and biological evalua­tion of polymeric micelles of Poloxamines and TPGS as Nanocarriers for Miltefosine deliv­ery. Int J Pharm 578:119057
Rathore C, Kulshrestha S, Lal UR, Gupta B, Pathania D (2020) Novel Thymoquinone loaded chitosan-lecithin micelles for effective wound healing: development, characteriza­tion, and preclinical evaluation. Carbohydr Polym 230:115659
NK (2004) Ethosomes: a novel vesicular car­rier for enhanced transdermal delivery of an anti-HIV agent. Indian J Pharm Sci 66:72–81
enhancers and retarders on percutaneous absorption of flurbiprofen from hydrogels. Int J Pharm 250:313–325
Rabasco AM (2005) Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes. Int J Pharm 298:1–12
phospholipids as carriers in skin topical appli­cation. J Nan Jing Med Univ 21:349–353.
https://doi.org/10.1016/s1007-4376(07) 60076-8
Athamna A, Athamna M (2005) A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: an in vivo study. J Antimicrob Chemother 55: 989–994
(2005) Mechanisms of action of novel skin penetration enhancers: phospholipid versus skin lipid liposomes. Int J Pharm 305:90–104
´
https://doi.org/
lez-Gaitano G (2020)
´
lez-Rodrı´guez ML,
70. Verma DD, Verma S, Blume G, Fahr A (2003) Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetra­tion and confocal laser scanning microscopy study. Eur J Pharm Biopharm 55:271–277
71. Pandey S, Goyani M, Dev MV, Fakir J (2009) Transferosomes: a novel approach of transder­mal drug. Deliv Sch Res Libr 1:143–150
72. Boinpally RR, Zhou SL, Poondru S, Devraj G, Jasti BR (2003) Lecithin vesicles for topical delivery of diclofenac. Eur J Pharm Biopharm 56:389–392
73. Jain S, Umamaheshwari RB, Bhadra D, Tripathi P, Jain P, Jain NK (2003) Ultra deformable liposomes: a recent tool for 78okffective transdermal drug delivery. Indian J Pharm Sci 65:223–231
74. Barry B (2002) Transdermal drug delivery. In: Aulton EM (ed) Pharmaceutics, the science of dosage forms design, 2nd edn. Harcourt Pub­lishers, Churchill Livingstone, Newyork, pp 499–433
75. Almira I, Blazek-welsh IA, Rhodes GD (2001) Maltodextrin— AAPS PharmSciTech 3:1–8
76. Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F (2008) Vesicles of non-ionic surfactants (Nio­somes) and drug delivery potential. Int J Pharm Sci Nanotech 1:1–8
77. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS (1985) The effect of non-ionic surfactant ves­icle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 37:237–242
78. Manosroi A, Wongtrakul P, Manosroi J, Sakai
H, Sugawara Characterization of vesicles prepared with var­ious non-ionic surfactants mixed with choles­terol. Colloids Surf B Biointerfaces 30:129– 138
79. Balasubramaniam A, Kumar VA, Pillai KS (2002) Formulation and in-vivo evaluation of niosome encapsulated daunorubicin hydro­chloride. Drug Dev Ind Pharm 28:1181– 1193
80. Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Poly­mer Sci Part C 51(1):135–153
81. Duncan R, synthetic-polymers as potential drug carriers. Adv Polym Sci 57:51–101
82. Duncan R, Lloyd JB, Kopecek J (1980) Deg­radation of side-chains of N-(2-hydroxypro­pyl) methacrylamide copolymers by lysosomal
Kopecek
based proniosomes.
F, Yuasa M et al (2003)
J (1984) Soluble
Polymer-Based Drug Delivery Systems: Design and Characterization 131
enzymes. Biochem Biophys Res Commun 94: 284–290
83. Khandare J, Minko T (2006) Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 31(4):359–397
84. Kopecek J, Kopeckova P, Minko T, Lu Z-R (2000) HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 50(1): 61–81
85. Duncan R (2006) Polymer conjugates as anti­cancer nanomedicines. Nat Rev Cancer 6(9): 688–701
86. Vogtle F, Richardt G, Werner N (2009) Introduction. In: Vo¨gtle F, Richardt G, Wer­ner N (eds) Dendrimer chemistry: concepts, syntheses, properties, applications. Academic, Wiley, pp 1–24
87. Buhleier E, Wehner W, Vo¨gtle F (1978) “Cascade”- and “nonskid-chain-like” synth­eses of molecular cavity topologies. Synthesis 9:155–158
88. Shi X, Majoros IJ, Baker JR (2005) Capillary electrophoresis of poly(amidoamine) dendri­mers: from simple derivatives to complex mul­tifunctional medical nanodevices. Mol Pharm 2:278–294
89. Bosman AW, Janssen HM, Meijer EW (1999) About dendrimers: structure, physical proper­ties, and applications. Chem Rev 99:1665– 1688
90. Kolhe P, Khandare J, Pillai O, Kannan S, Lieh­Lai M, Kannan RM (2006) Preparation, cel­lular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. Biomaterials 27: 660–669
91. Menjoge AR, Kannan RM, Tomalia DA (2010) Dendrimer-based drug and imaging conjugates: design considerations for nano­medical applications. Drug Discov Today 15: 171–185
92. Tomalia DA (1991) Dendrimer research. Sci­ence 252:1231
93. Tomalia DA (2009) In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 11:1251–1310
94. Tomalia DA (2012) Interview: an architec­tural journey: from trees, dendrons/dendri­mers to nanomedicine. Interview by Hannah Stanwix. Nanomedicine 7:953–956
95. Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGyla­tion. Adv Drug Deliv Rev 54(4):459–476
96. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977) Effect of covalent attachment of polyethyleneglycol on immu­nogenicity and circulating life of bovine liver catalase. J Biol Chem 252(11):3582–3586
97. Duncan R, Gilbert HRP, Carbajo RJ, Vicent MJ (2008) Polymer masked-unmasked pro­tein therapy. 1. Bioresponsive dextrin-trypsin and -melanocyte stimulating hormone conju­gates designed for α- amylase activation. Bio­macromolecules 9(4):1146–1154
98. Andreani T, Kiill CP, de Souza ALR, Fan­gueiro JF, Doktorovova´ S, Garcia ML, Gra-
˜
mia
o MPD, Silva AM, Souto EB (2015) E_ect of cryoprotectants on the reconstitution of silica nanoparticles produced by sol–gel tech­nology. J Therm Anal Calorim 120:1001– 1007
99. Mathurin J, Pancani E, Deniset-Besseau A, Kjoller K, Prater CB, Gref R, Dazzi A (2018) How to unravel the chemical structure and component localization of individual drug-loaded polymeric nanoparticles by using tapping AFM-IR. Analyst 143:5940– 5949
100. Mourdikoudis S, Pallares RM, Thanh NT (2018) Characterization techniques for nano­particles: comparison and complementarity upon studying nanoparticle properties. Nanoscale 10:12871–12934
101. Lu M, Yang X, Yang Y, Qin P, Wu X, Cai Z (2017) Nanomaterials as assisted matrix of laser desorption/ionization time-of-flight mass spectrometry for the analysis of small molecules. Nano 7:87
102. Yang Y, Jiang Y, Xu J, Yu J (2007) Conduct­ing polymeric nanoparticles synthesized in reverse micelles and their gas sensitivity based on quartz crystal microbalance. Poly­mer 48:4459–4465
103. Dazon C, Witschger O, Bau S, Fierro V, Lle­wellyn PL (2019) Nanomaterial identification of powders: comparing volume specific sur­face area, X-ray di_raction and scanning elec­tron microscopy methods. Environ Sci Nano 6:152–162
104. Zielinska A, Nowak I, Souto EB (2020) Loading, release profile and accelerated stability assessment of monoterpenes-loaded solid lipid nanoparti­cles (SLN). Pharm Dev Technol 25:1–13
Ferreira NR, Feliczak-Guzik A,
Chapter 7
Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation
Manisha, Pritam Pal, Pradyut Das, and Vishwa Ranjan Upadhyay
Abstract
In order to address the shortcomings of traditional therapeutic modalities, this study offers a thorough review of stimuli-responsive drug delivery systems (DDS) for programmed site-specific release that are based on both endogenous and exogenous stimuli. This work focuses on the smart materials and mecha­nism of action of several stimuli-responsive polymeric carriers, which are important in both the extracellular and intracellular domains of diseased tissues or cells. Research is being conducted globally to design new stimuli-responsive carriers, both internal and external, for biotechnological applications in general and biomedical and/or pharmaceutical applications in particular. This is because science has an ever-expanding body of knowledge and awareness. An essential component of designing so-called smart DDS, which sophisticatedly regulates dose loading, sustained release, individual variability, and ta rgeted permeability, is the carriers’ dual-/multi-responsive, internal, and even external behaviors. Various stimulus-responsive DDS have been developed, proposed, and utilized thus far. These include systems responsive to electrical, magnetic, pH, temperature, photo/light-induced reactions, and redox stimuli. Additionally, dual and multi-responsive DDS, which combine two or more of these stimuli, have been explored for enhanced therapeutic efficiency. In order to close the research gap, a number of difficult issues still need to be resolved despite the tremendous advancements made in the DDS field. To fill in the gaps in the literature, an attempt has been made to draw attention to those important issues in this context. As a result, the focus was on the mechanisms of drug release and the clinical applications of exogenous and endogenous stimuli­responsive DDS.
Key words Stimuli-responsive, Drug delivery, Polymeric carriers, Endogenous, Exogenous, Nanotechnology

1 Introduction

The landscape of drug delivery systems has evolved significantly over the past few decades. Traditional drug delivery methods, such as oral and intravenous administration, have been the backbone of therapeutic practices. While effective, these methods often present challenges, including suboptimal bioavailability, systemic side effects, and lack of targeted delivery [ driven the quest for more advanced drug delivery systems,
133
1]. These limitations have
134 Manisha et al.
culminating in the development of stimuli-responsive drug deliver y systems (SRDDS). These systems are engineered to release thera­peutic agents in response to specific physiological or external sti­muli, offering a controlled, targeted, and efficient means of drug delivery [
2].
2 Definition of Stimuli-Responsive Drug Delivery Systems
Stimuli-responsive drug delivery systems are advanced drug deliv­ery platforms designed to release therapeutic agents in response to specific internal or external triggers [ enhance therapeutic efficacy, minimize side effects, and provide controlled and targeted delivery of drugs. The underlying concept is to ensure that the drugs are released precisely where and when they are needed, responding to specific physiological conditions or external signals.
3]. These systems aim to

2.1 Types of Stimuli

Stimuli that trigger drug release in SRDDS can be broadly categor­ized into internal and external stimuli (Fig.
1).
1. Internal Stimuli
(a) pH: Variations in pH levels within different body environ-
ments (e.g., acidic pH in the stomach or tumor tissues)
(b) Temperature: Localized hyperthermia in inflamed or
cancerous tissues
(c) Redox potential: Differences in oxidative and reductive
conditions inside and outside cells
(d) Enzymatic activity:
Presence
of specific enzymes at
disease sites
Fig. 1 Classification of various types of stimuli
Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 135
2. External Stimuli
(e) Light: Controlled exposure to specific wavelengths of light
(f) Magnetic Fields: Application of external magnetic fields
(g) Electric Fields: Application of electric currents or fields

3 Mechanism of Stimuli Responsiveness

The mechanisms by which SRDDS respond to stimuli involve various physical, chemical, and biological processes that trigger drug release. Understanding these mechanisms is crucial for designing effective stimuli-responsive systems.

3.1 pH-Responsive Systems

Mechanism: These systems utilize materials that undergo changes
in solubility, charge, or structure in response to pH variations (Fig. 2). For example, polymers containing acidic or basic groups can swell, dissolve, or degrade at specific pH levels, releasing the encapsulated drug.
Example: Poly(methacrylic acid) nanoparticles that release drugs in
acidic tumor microenvironments.
Fig. 2 Mechanism of action of pH-responsive drug delivery system
136 Manisha et al.
Fig. 3 Mechanism of action of temperature-responsive drug delivery system
3.2 Temperature­Responsive Systems
3.3 Light­Responsive Systems
3.4 Redox­Responsive Systems
3.5 Magnetic­Responsive Systems
Mechanism: These systems are based on materials that exhibit phase
transitions at certain temperatures (Fig.
3). Thermo-responsive
polymers, such as poly(N-isopropylacrylamide), can change from a hydrophilic to a hydrophobic state at a critical tempera­ture, causing drug release.
Example: Injectable hydrogels that solidify at body temperature,
allowing localized drug delivery.
Mechanism: Light-responsive systems use photo-responsive mate-
rials that undergo structural changes upon exposure to specific wavelengths of light. This can include photoisomerization, photodegradation, or photothermal effects.
Example: Gold nanoparticles that convert light energy into heat,
triggering drug release.
Mechanism: Redox-responsive systems often utilize disulfide lin-
kages or other redox-responsive bonds that are stable under extracellular oxidative conditions but cleaved in the reductive intracellular environment, leading to drug release (Fig.
4).
Example: Micelles with disulfide cross-linked cores that degrade in
the presence of intracellular glutathione.
Mechanism: These systems incorporate magnetic nanoparticles that
can be directed and heated by an external magnetic field, causing drug release through thermal or mechanical means.
Example: Magnetic liposomes that release drugs upon exposure to
an alternating magnetic field.
3.6 Electric­Responsive Systems
3.7 Enzyme­Responsive Systems
Mechanism: These systems use materials that undergo electro-
chemical reactions or changes in conductivity upon exposure to electric fields, enabling controlled drug release.
Example: Conductive polymers that release drugs in response to
applied electrical stimuli.
Mechanism: These systems are designed with substrates that are
specifically cleaved by enzymes present at disease sites. The enzymatic action breaks down the carrier matrix or releases the drug from its conjugate.
Example: Polymeric nanoparticles containing peptide sequences
cleavable by matrix metalloproteinases (MMPs) overexpressed in tumors.
Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 137

4 Materials

4.1 pH-Responsive Materials

Fig. 4 Mechanism of action of redox-responsive drug delivery system
The phenomena that affect an activity at a specific location or target tissue to bring about beneficial activities for the drug release via a variety of mechanisms is included in the stimuli-responsive drug delivery system. These materials are referred to as “environmentally responsive materials” or “stimuli-responsive materials” [
5 for a visualization of different types of materials.
Fig.
4, 5]. See
It is necessary for a pH-responsive drug delivery system (DDS) to protect the drug capsule while it is in the bloodstream (pH 7.3–7.4) and to release the drug or trigger particular actions (like cell-penetrating ability) when the tumor interstitial space (pH 6.8–7.2) or intracellular compartments (pH 4.5–5.5), endo­somes (pH 5–6), and cytoplasm (pH slightly above pH 7.0) are reached [115–117]. Paclitaxel (PTX) and antagomir-10b were developed to be delivered via a pH-responsive antimicrobial peptide-mediated liposomal delivery system in mice with metastatic
138 Manisha et al.
Fig. 5 Classification of various types of materials
mammary tumor models. Antagomirs are single-stranded RNA analogues that have undergone chemical modification and have been conjugated with cholesterol. This increases their stability and function by hybridizing with mature miRNA and inhibiting its activity [
6]. One well-known cytotoxic drug is paclitaxel. The
researchers attached [D]-H6L9, a previously reported pH-dependent antimicrobial peptide to the liposome surface
7
[
]. pH-responsive materials can be developed using materials with ionizable groups, and non-conventional techniques. When metformin hydrochloride (MH) was added to mesoporous bioglass (MBG) as a model drug, it effectively functions as a pH-responsive carrier. Afterward, hydroxyapatite (HAp) was added to the MBG pores at different concentrations and times to regulate the release of MH. Following drug loading and HAp mineralization volume, and surface decreased by longer mineralization durations and higher ion con­centrations, suggesting that prolonged mineralization and higher ion concentrations improve HAp mineralization Drug-loading effi­ciency stayed unchanged despite the breakdown of HAp in acidic conditions, which changed the MH release profile based on miner­alization time and ion concentration. These observat that this pH-responsive material tic agents targeting tumors and inflammatory sites [ ples of materials that
these materials can be made using
, a decrease in pore size,
area was observed. Pore size was also further
ions suggest
is a promising car rier for therapeu-
8]. Key exam-
respond to pH are provided in Table
1.
hermo-
4.2 T Responsive Materials
Thermo-responsive materials exhibit changes in their physical properties or conformations in response to temperature variations. These materials are utilized in various biomedical applications, such as tissue engineering and drug delivery. However, the balance between hydrophilic and hydrophobic properties, as well as the